[1]
|
Zlokovic, B.V. and Apuzzo, M.L. (1998) Strategies to Circumvent Vascular Barriers of the Central Nervous System. Neurosurgery, 43, 877-878. https://doi.org/10.1097/00006123-199810000-00089
|
[2]
|
Terstappen, G.C., Meyer, A.H., Bell, R.D., et al. (2021) Strategies for Delivering Therapeutics across the Blood-Brain Barrier. Nature Reviews Drug Discovery, 20, 362-383. https://doi.org/10.1038/s41573-021-00139-y
|
[3]
|
Redzic, Z. (2011) Molecular Bi-ology of the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers: Similarities and Differences. Fluids and Barriers of the CNS, 8, Article No. 3. https://doi.org/10.1186/2045-8118-8-3
|
[4]
|
Zlokovic, B.V. (2008) The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron, 57, 178-201.
https://doi.org/10.1016/j.neuron.2008.01.003
|
[5]
|
Brightman, M.W. (1969) Junctions between Intimately Apposed Cell Membranes in the Vertebrate Brain. Journal of Cell Biology, 40, 648-677. https://doi.org/10.1083/jcb.40.3.648
|
[6]
|
Volterra, A. and Meldolesi, J. (2005) Astrocytes, from Brain Glue to Communication Elements: The Revolution Continues. Nature Reviews Neuroscience, 6, 626-640. https://doi.org/10.1038/nrn1722
|
[7]
|
Winkler, E.A., Bell, R.D. and Zlokovic, B.V. (2011) Central Nervous System Pericytes in Health and Disease. Nature Neuroscience, 14, 1398-1405. https://doi.org/10.1038/nn.2946
|
[8]
|
Abbott, N.J. (2002) Astrocyte—Endothelial Interactions and Blood-Brain Barrier Permeability. Journal of Anatomy, 200, 629-638. https://doi.org/10.1046/j.1469-7580.2002.00064.x
|
[9]
|
Abbott, N.J., Ronnback, L. and Hansson, E. (2006) Astrocyte—Endothelial Interactions at the Blood-Brain Barrier. Nature Reviews Neuroscience, 7, 41-53. https://doi.org/10.1038/nrn1824
|
[10]
|
Zonta, M., Angulo, M.C., Gobbo, S., et al. (2003) Neuron-to-Astrocyte Sig-naling Is Central to the Dynamic Control of Brain Microcirculation. Nature Neuroscience, 6, 43-50. https://doi.org/10.1038/nn980
|
[11]
|
Iadecola, C. (2004) Neurovascular Regulation in the Normal Brain and in Alz-heimer’s Disease. Nature Reviews Neuroscience, 5, 347-360. https://doi.org/10.1038/nrn1387
|
[12]
|
Iadecola, C. and Nedergaard, M. (2007) Glial Regulation of the Cerebral Microvasculature. Nature Neuroscience, 10, 1369-1376. https://doi.org/10.1038/nn2003
|
[13]
|
Hawkins, B.T. and Davis, T.P. (2005) The Blood-Brain Barrier/Neurovascular Unit in Health and Disease. Pharmacological Reviews, 57, 173-185. https://doi.org/10.1124/pr.57.2.4
|
[14]
|
Begley, D.J. (2004) ABC Transporters and the Blood-Brain Barrier. Current Pharmaceutical Design, 10, 1295-312.
https://doi.org/10.2174/1381612043384844
|
[15]
|
Wong, K., Riaz, M., Xie, Y., et al. (2019) Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. International Journal of Molecular Sciences, 20, Article 381.
https://doi.org/10.3390/ijms20020381
|
[16]
|
Pardridge, W.M. (2020) Treatment of Alzheimer’s Disease and Blood—Brain Barrier Drug Delivery. Pharmaceuticals, 13, Article 394. https://doi.org/10.3390/ph13110394
|
[17]
|
Pardridge, W.M. (2005) The Blood-Brain Barrier: Bottleneck in Brain Drug Development. NeuroRX, 2, 3-14.
https://doi.org/10.1602/neurorx.2.1.3
|
[18]
|
Abbott, N.J., Patabendige, A.A.K., Dolman, D.E.M., et al. (2010) Structure and Function of the Blood—Brain Barrier. Neurobiology of Disease, 37, 13-25. https://doi.org/10.1016/j.nbd.2009.07.030
|
[19]
|
St-Amour, I., Paré, I., Alata, W., et al. (2013) Brain Bioavailability of Human Intravenous Immunoglobulin and Its Transport through the Murine Blood–Brain Barrier. Journal of Cerebral Blood Flow & Metabolism, 33, 1983-1992.
https://doi.org/10.1038/jcbfm.2013.160
|
[20]
|
Urquhart, L. (2023) Top Companies and Drugs by Sales in 2022. Na-ture Reviews Drug Discovery, 22, 260.
https://doi.org/10.1038/d41573-023-00039-3
|
[21]
|
Thomsen, M.S., Johnsen, K.B., Kucharz, K., et al. (2022) Blood—Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles. Pharmaceutics, 14, Article 2237. https://doi.org/10.3390/pharmaceutics14102237
|
[22]
|
Maussang, D., Rip, J., Van Kregten, J., et al. (2016) Gluta-thione Conjugation Dose-Dependently Increases Brain-Specific Liposomal Drug Delivery in Vitro and in Vivo. Drug Discovery Today: Technologies, 20, 59-69.
https://doi.org/10.1016/j.ddtec.2016.09.003
|
[23]
|
Wiklander, O.P., Nordin, J.Z., O’loughlin, A., et al. (2015) Ex-tracellular Vesicle in Vivo Biodistribution Is Determined by Cell Source, Route of Administration and Targeting. Journal of Extracellular Vesicles, 4, Article ID: 26316.
https://doi.org/10.3402/jev.v4.26316
|
[24]
|
Sharma, G., Lakkadwala, S., Modgil, A. and Singh, J. (2016) The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain. International Journal of Molecular Sciences, 17, Article 806.
https://doi.org/10.3390/ijms17060806
|
[25]
|
Rastall, D.P. and Amalfitano, A. (2015) Recent Advances in Gene Therapy for Lysosomal Storage Disorders. The Application of Clinical Genetics, 8, 157-169. https://doi.org/10.2147/TACG.S57682
|
[26]
|
Moos, T. and Morgan, E.H. (2000) Transferrin and Transferrin Re-ceptor Function in Brain Barrier Systems. Cellular and Molecular Neurobiology, 20, 77-95. https://doi.org/10.1023/A:1006948027674
|
[27]
|
Zhou, X., Smith, Q.R. and Liu, X. (2021) Brain Penetrating Pep-tides and Peptide—Drug Conjugates to Overcome the Blood—Brain Barrier and Target CNS Diseases. WIREs Nano-medicine and Nanobiotechnology, 13, e1695.
https://doi.org/10.1002/wnan.1695
|
[28]
|
Moos, T., Oates, P.S. and Morgan, E.H. (1998) Expression of the Neu-ronal Transferrin Receptor Is Age Dependent and Susceptible. Journal of Comparative Neurology, 398, 420-430.
https://doi.org/10.1002/(SICI)1096-9861(19980831)398:3<420::AID-CNE8>3.0.CO;2-1
|
[29]
|
Zlokovic, B.V. (2005) Neurovascular Mechanisms of Alzheimer’s Neurodegeneration. Trendsin Neurosciences, 28, 202-208. https://doi.org/10.1016/j.tins.2005.02.001
|
[30]
|
Begley, D.J. and Brightman, M.W. (2003) Structural and Functional Aspects of the Blood-Brain Barrier. Progress in Drug Research, 61, 39-78. https://doi.org/10.1007/978-3-0348-8049-7_2
|
[31]
|
Ullman, J.C., Arguello, A., Getz, J.A., et al. (2020) Brain De-livery and Activity of a Lysosomal Enzyme using A Blood-Brain Barrier Transport Vehicle in Mice. Science Transla-tional Medicine, 12, eaay1163.
https://doi.org/10.1126/scitranslmed.aay1163
|
[32]
|
Cummings, J., Lee, G., Zhong, K., Fonseca, J. and Taghva, K. (2021) Alzheimer’s Disease Drug Development Pipeline: 2021. Alzheimer’s & Dementia, 7, e12179. https://doi.org/10.1002/trc2.12179
|
[33]
|
Yu, Y.J., Zhang, Y., Kenrick, M., et al. (2011) Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target. Science Translational Medicine, 3, 84ra44.
https://doi.org/10.1126/scitranslmed.3002230
|
[34]
|
Bien-Ly, N., Yu, Y.J., Bumbaca, D., et al. (2014) Transferrin Receptor (TfR) Trafficking Determines Brain Uptake of TfR Antibody Affinity Variants. Journal of Experimental Medi-cine, 211, 233-244.
https://doi.org/10.1084/jem.20131660
|
[35]
|
Couch, J.A., Yu, Y.J., Zhang, Y., et al. (2013) Addressing Safety Lia-bilities of TfR Bispecific Antibodies that Cross the Blood-Brain Barrier. Science Translational Medicine, 5, 183ra57. https://doi.org/10.1126/scitranslmed.3005338
|
[36]
|
Yu, Y.J., Atwal, J.K., Zhang, Y., et al. (2014) Therapeutic Bispecific Antibodies cross the Blood-Brain Barrier in Nonhuman Primates. Science Translational Medicine, 5, 261ra154. https://doi.org/10.1126/scitranslmed.3009835
|
[37]
|
Moody, P.R., Sayers, E.J., Magnusson, J.P., Alexander, C., Borri, P., Watson, P. and Jones, A.T. (2015) Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor: Ligand Complexes. Molecular Therapy, 23, 1888-1898. https://doi.org/10.1038/mt.2015.178
|
[38]
|
Hoy, S.M. (2023) Lecanemab: First Approval. Drugs, 83, 359-365. https://doi.org/10.1007/s40265-023-01851-2
|
[39]
|
Hultqvist, G., Syvanen, S., Fang, X.T., et al. (2017) Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. Theranostics, 7, 308-318. https://doi.org/10.7150/thno.17155
|
[40]
|
Morrison, J.I., Metzendorf, N.G., Rofo, F., Petrovic, A. and Hultqvist, G. (2023) A Single-Chain Fragment Constant Design Enables Easy Production of a Monovalent Blood-Brain Barrier Transporter and Provides an Improved Brain Uptake at Elevated Doses. Journal of Neurochemistry, 165, 413-425. https://doi.org/10.1111/jnc.15768
|
[41]
|
Rofo, F., Metzendorf, N.G., Saubi, C., et al. (2022) Blood-Brain Barrier Penetrating Neprilysin Degrades Monomeric Amyloid-Beta in a Mouse Model of Alzheimer’s Disease. Alzheimer's Re-search & Therapy, 14, Article No. 180.
https://doi.org/10.1186/s13195-022-01132-2
|
[42]
|
Arguello, A., Mahon, C.S., Calvert, M.E.K., et al. (2022) Mo-lecular Architecture Determines Brain Delivery of a Transferrin Receptor-Targeted Lysosomal Enzyme. Journal of Ex-perimental Medicine, 219, e20211057.
https://doi.org/10.1084/jem.20211057
|
[43]
|
陈志南. 抗体药物研发[M]. 上海: 上海交通大学出版社, 2020: 48-50.
|
[44]
|
Przybilla, M.J., Stewart, C., Carlson, T.W., et al. (2021) Examination of a Blood-Brain Barrier Targeting Beta-Galactosidase-Monoclonal Antibody Fusion Protein in a Murine Model of GM1-Gangliosidosis. Molecular Genet-ics and Metabolism Reports, 27, Article ID: 100748. https://doi.org/10.1084/jem.20211057
|
[45]
|
Roshanbin, S., Xiong, M., Hultqvist, G., et al. (2022) In Vivo Imaging of Alpha-Synuclein with Antibody-Based PET. Neuropharma-cology, 208, Article ID: 108985. https://doi.org/10.1016/j.neuropharm.2022.108985
|
[46]
|
Bonvicini, G., Syvanen, S., Andersson, K.G., Haaparanta-Solin, M., López-Picón, F. and Sehlin, D. (2022) ImmunoPET Imaging of Amy-loid-Beta in a Rat Model of Alzheimer’s Disease with a Bispecific, Brain-Penetrating Fusion Protein. Translational Neurodegeneration, 11, Article No. 55. https://doi.org/10.1186/s40035-022-00324-y
|
[47]
|
Mayor, S. and Pagano, R.E. (2007) Pathways of Clathrin-Independent Endocytosis. Nature Reviews Molecular Cell Biology, 8, 603-612. https://doi.org/10.1038/nrm2216
|
[48]
|
Tian, X., Liu, X., Ding, J., et al. (2023) An Anti-CD98 Antibody Displaying pH-Dependent Fc-Mediated Tumour-Specific Activity against Multiple Cancers in CD98-Humanized Mice. Nature Bio-medical Engineering, 7, 8-23.
https://doi.org/10.1038/s41551-022-00956-5
|
[49]
|
Bogen, J.P., Hinz, S.C., Grzeschik, J., et al. (2019) Dual Func-tion pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma. Frontiers in Immu-nology, 10, Article 1892.
https://doi.org/10.3389/fimmu.2019.01892
|
[50]
|
Liu, X., Tian, X., Hao, X., et al. (2022) A Cross-Reactive pH-Dependent EGFR Antibody with Improved Tumor Selectivity and Penetration Obtained by Structure-Guided Engi-neering. Molecular Therapy-Oncolytics, 27, 256-269.
https://doi.org/10.1016/j.omto.2022.11.001
|
[51]
|
Sade, H., Baumgartner, C., Hugenmatter, A., Moessner, E., Freskgård, P.-O. and Niewoehner, J. (2014) A Human Blood-Brain Barrier Transcytosis Assay Reveals Antibody Transcytosis Influenced by pH-Dependent Receptor Binding. PLOS ONE, 9, e96340. https://doi.org/10.1371/journal.pone.0096340
|
[52]
|
Watkins, J.M. and Watkins, J.D. (2022) An Engineered Mono-valent Anti-TNF-α Antibody with pH-Sensitive Binding Abrogates Immunogenicity in Mice following a Single Intrave-nous Dose. The Journal of Immunology, 209, 829-839.
https://doi.org/10.4049/jimmunol.2101180
|
[53]
|
Zhang, Y., Du, X., Liu, M., et al. (2019) Hijacking Anti-body-Induced CTLA-4 Lysosomal Degradation for Safer and More Effective Cancer Immunotherapy. Cell Research, 29, 609-627. https://doi.org/10.1038/s41422-019-0184-1
|
[54]
|
Lee, P.S., Macdonald, K.G., Massi, E., et al. (2022) Im-proved Therapeutic Index of an Acidic pH-Selective Antibody. mAbs, 14, Article ID: 2024642. https://doi.org/10.1080/19420862.2021.2024642
|
[55]
|
Li, Y., Liu, J., Chen, W., et al. (2023) A pH-Dependent An-ti-CD47 Antibody that Selectively Targets Solid Tumors and Improves Therapeutic Efficacy and Safety. Journal of He-matology & Oncology, 16, Article No. 2.
https://doi.org/10.1186/s13045-023-01399-4
|
[56]
|
Igawa, T., Ishii, S., Tachibana, T., et al. (2010) Antibody Recy-cling by Engineered pH-Dependent Antigen Binding Improves the Duration of Antigen Neutralization. Nature Biotech-nology, 28, 1203-1207.
https://doi.org/10.1038/nbt.1691
|
[57]
|
Sheridan, D., Yu, Z.X., Zhang, Y., et al. (2018) Design and Preclinical Characterization of ALXN1210: A Novel Anti-C5 Antibody with Extended Duration of Action. PLOS ONE, 13, e0195909.
https://doi.org/10.1371/journal.pone.0195909
|
[58]
|
Sulea, T., Rohani, N., Baardsnes, J., et al. (2020) Struc-ture-Based Engineering of pH-Dependent Antibody Binding for Selective Targeting of Solid-Tumor Microenvironment. mAbs, 12, Article ID: 1682866.
https://doi.org/10.1080/19420862.2019.1682866
|
[59]
|
Chaparro-Riggers, J., Liang, H., Devay, R.M., et al. (2012) Increasing Serum Half-Life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-Sensitive Binding to PCSK9. Journal of Biological Chemistry, 287, 11090-11097. https://doi.org/10.1074/jbc.M111.319764
|
[60]
|
Bonvin, P., Venet, S., Fontaine, G., et al. (2015) De Novo Isolation of Antibodies with pH-Dependent Binding Properties. MAbs, 7, 294-302. https://doi.org/10.1080/19420862.2015.1006993
|
[61]
|
Zou, W., Huang, C., Sun, Q., Zhao, K., Gao, H., Su, R. and Li, Y. (2022) A Stepwise Mutagenesis Approach Using Histidine and Acidic Amino Acid to Engineer Highly pH-Dependent Protein Switches. 3 Biotech, 12, Article No. 21.
https://doi.org/10.1007/s13205-021-03079-x
|
[62]
|
Pardridge, W.M. (2022) Blood-Brain Barrier Delivery for Ly-sosomal Storage Disorders with IgG-Lysosomal Enzyme Fusion Proteins. Advanced Drug Delivery Reviews, 184, Arti-cle No. 114234.
https://doi.org/10.1016/j.addr.2022.114234
|
[63]
|
Islam, M.R., Grubb, J.H. and Sly, W.S. (1993) C-Terminal Pro-cessing of Human β-Glucuronidase. The Propeptide Is Required for Full Expression of Catalytic Activity, Intracellular Retention, and Proper Phosphorylation. The Journal of Biological Chemistry, 268, 22627-22633. https://doi.org/10.1016/S0021-9258(18)41574-8
|
[64]
|
Wilson, P.J., Morris, C.P., Anson, D.S., et al. (1990) Hunter Syndrome: Isolation of an Iduronate-2-Sulfatase cDNA Clone and Analysis of Patient DNA. Proceedings of the National Academy of Sciences of the United States of America, 87, 8531-8535. https://doi.org/10.1073/pnas.87.21.8531
|
[65]
|
Kariolis, M.S., Wells, R.C., Getz, J.A., et al. (2020) Brain Delivery of Therapeutic Proteins Using an Fc Fragment Blood-Brain Barrier Transport Vehicle in Mice and Monkeys. Science Translational Medicine, 12, eaay1359.
https://doi.org/10.1126/scitranslmed.aay1359
|
[66]
|
Mihara, E., Watanabe, S., Bashiruddin, N.K., et al. (2021) Las-so-Grafting of Macrocyclic Peptide Pharmacophores Yields Multi-Functional Proteins. Nature Communications, 12, Ar-ticle No. 1543.
https://doi.org/10.1038/s41467-021-21875-0
|
[67]
|
Ito, K., Passioura, T. and Suga, H. (2013) Technologies for the synthesis of mRNA-Encoding Libraries and Discovery of Bioactive Natural Product-Inspired Non-Traditional Macrocy-clic Peptides. Molecules, 18, 3502-3528.
https://doi.org/10.3390/molecules18033502
|
[68]
|
Sakai, K., Sugano-Nakamura, N., Mihara, E., et al. (2023) De-signing Receptor Agonists with Enhanced Pharmacokinetics by Grafting Macrocyclic Peptides into Fragment Crystalliza-ble Regions. Nature Biomedical Engineering, 7, 164-176.
https://doi.org/10.1038/s41551-022-00955-6
|
[69]
|
Yamamoto, R., Yoden, E., Tanaka, N., et al. (2021) Nonclinical Safety Evaluation of Pabinafusp Alfa, an Anti-Human Transferrin Receptor Antibody and Iduronate-2-Sulfatase Fusion Protein, for the Treatment of Neuronopathic Mucopolysaccharidosis Type II. Molecular Genetics and Metabolism Re-ports, 27, Article ID: 100758.
https://doi.org/10.1016/j.ymgmr.2021.100758
|
[70]
|
Ruano-Salguero, J.S. and Lee, K.H. (2020) Antibody Transcytosis across Brain Endothelial-Like Cells Occurs Nonspecifically and Independent of FcRn. Scientific Reports, 10, Article No. 3685.
https://doi.org/10.1038/s41598-020-60438-z
|
[71]
|
DE LA Rosa, A., Metzendorf, N.G., Morrison, J.I., et al. (2022) Introducing or Removing Heparan Sulfate Binding Sites Does Not Alter Brain Uptake of the Blood-Brain Barrier Shuttle scFv8D3. Scientific Reports, 12, Article No. 21479. https://doi.org/10.21203/rs.3.rs-2166577/v1
|
[72]
|
Clarke, E., Stocki, P., Sinclair, E.H., et al. (2022) A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson’s Disease. Pharmaceutics, 14, Article 1335. https://doi.org/10.3390/pharmaceutics14071335
|
[73]
|
Hanzatian, K.D, Schwartz, A., Gizatullin, F., et al. (2018) Brain Uptake of Multivalent and Multi-Specific DVD-Ig Proteins after Systemic Admin-istration. mAbs, 10, 765-777. https://doi.org/10.1080/19420862.2018.1465159
|